Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.

Yves AlloryStephane CulineClémentine KruckerJacqueline FontugneValentin HarterChristian Pfister

Published in: The Journal of urology (2023)

In the VESPER trial, we did not observe evidence for association of VH/DD with outcomes after NAC, but the specific presence of a predominant squamous differentiation or micropapillary subtype may be associated with shorter PFS.

Keyphrases

phase iii
study protocol
phase ii
clinical trial
transcription factor
high grade
open label
low grade